Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Los Bonos 1 (no aplicable en España), 2 (Marcas y Diseños) y 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentran cerrados desde el 20/08/2025. La solicitud del Bono 4 sigue abierta. Más adelante se informará sobre la reapertura de estos Bonos
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
165
resultados
Última actualización
28/09/2025 [07:28:00]
Resultados 75 a 100 de 165
Resumen de: MX2025009625A
HTT nucleic acid trans-splicing molecules are described, which include a coding domain comprising one or more <i>HTT</i> exons, a splice site, and a binding domain that binds a target intron of a <i>HTT</i> pre-mRNA. HTT nucleic acid trans-splicing molecules described herein may also be used in combination with, e.g., MSH3 binding domains arranged in tandem with an HTT binding domain,<i> </i>MSH3 nucleic acid trans-splicing molecules, <i>MSH3</i> splice modulators, anti-sense oligonucleotides or anti-sense RNA to either of <i>MSH3</i> or <i>HTT</i> and <i>MSH3</i> or <i>HTT</i> microRNA (miRNA) and constructs encoding same. Compositions comprising nucleic acid trans-splicing molecules described herein are also encompassed, as are compositions comprising combinations of nucleic acid trans-splicing molecules with additional therapeutic agents (e.g., <i>MSH3</i> nucleic acid trans-splicing molecules, <i>MSH3</i> splice modulators, anti-sense oligonucleotides or anti-sense RNA to either of <i>MSH3</i> or <i>HTT</i>). Nucleic acid trans-splicing molecules may be used alone or in combination with additional therapeutic agents in methods for treating Huntington's Disease (HD). Nucleic acid trans-splicing molecules are also described herein for use, alone or in combination with additional therapeutic agents, in treating HD or in the preparati
Resumen de: US2024342309A1
Disclosed herein are recombinant gene therapy vectors comprising a PTEN-induced kinase 1 (PINK1) encoding gene that is operatively linked to a promoter and methods of using the recombinant therapy vectors for inhibiting, reducing, or delaying degeneration or death of neurons of a subject.
Resumen de: MD20250033A2
Disclosed in the present invention are a cannabinoid composition and an application thereof in the preparation of a drug for treating neurodegenerative diseases, for use in solving the existing problems of large side effects and poorer therapeutic efficacy after long-term use of a drug for treating neurodegenerative diseases. The cannabinoid composition comprises cannabidiol and cannabigerol which are in a mass ratio of 1:1-1:10 or 1:0.3-1:0.5 or 1:0.5-1:0.7 or 1:0.7-1:1. According to the present invention, by using an experimental method for inducing the differentiation of fibroblasts into dopamine nerve cells to observe the morphologies and number of cells after the inducing of cell differentiation and detect an expression level of DA-related factors, and to screen effects of common different cannabinoids and combinations thereof on the inducing of the differentiation of fibroblasts into dopaminergic neurons, it is found that a CBD+CBG combination has optimal effects on the improvement of the survival ability and dopamine secretingability of the dopaminergic neurons, does not contain the addictive substance THC and thus greatly reduces the side effects of a drug, and can be used for preparing a drug for treating neurodegenerative diseases.
Resumen de: NZ763247A
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include motor dysfunction, aggregation of alpha-synuclein, neurodegeneration, cognitive decline and dementia. Such neurodegenerative diseases include Parkinson’s disease, dementia withLewy bodies, diffuse Lewy body disease, pure autonomic failure, multiple system atrophy, neuronopathic Gaucher’s disease and Alzheimer’s disease.
Resumen de: NZ753881A
Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimer’s disease and Parkinson’s disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
Resumen de: KR20250129577A
본 발명은 담수어 가수분해물을 포함하는 알츠하이머성 치매의 예방, 개선 또는 치료용 조성물에 관한 것으로, 보다 상세하게는, 본 발명의 가물치, 동자개, 메기, 무지개송어, 붕어, 쏘가리, 잉어, 향어, 미꾸라지, 또는 빙어 등의 담수어의 효소 가수분해물, 상기 가수분해물로부터 얻은 분획물, 상기 분획물로부터 분리한 펩타이드는 우수한 β-세크레타제 저해 활성을 가지므로, 이들을 알츠하이머성 치매의 예방, 개선 또는 치료를 위한 의약, 식품 등에 활용할 수 있다.
Resumen de: WO2025176909A1
The present invention relates to a solid composition, and its use in the treatment of Parkinson's disease, comprising at least two compartments, a first active pharmaceutical ingredient (API) and a second API, preferably for increasing uptake of the second API thereby optimizing its use in the treatment of Parkinson's disease, in particular improving its clinical activity and reducing its side effects associated with the treatment of Parkinson's disease.
Resumen de: WO2025176317A1
The present invention relates to a solid composition for use in the treatment of Parkinson's disease comprising at least two compartments, a first active pharmaceutical ingredient (API) and a second API, preferably for increasing uptake of the second API and reducing side effects associated with the treatment of Parkinson's disease.
Resumen de: WO2025179300A1
Methods, compositions, and kits are capable of detecting, identifying, diagnosing, prognosing, assessing, monitoring, and/or treating a neurological injury such as acute TBI and distinguishing geriatric TBI from conditions such as dementia, Alzheimer's Disease, Parkinson's disease and the like. Also disclosed are methods of testing elderly patients who have or are suspected of having traumatic brain injury using panels of biomarkers that distinguish TBI from dementia, and, optionally, treating such patients for TBI or dementia based upon the results of the biomarker tests.
Resumen de: WO2025179301A1
Embodiments are directed to methods for treating neurodegenerative disease by administering anti-viral compounds to subjects having or at risk of developing neurodegenerative diseases such as Alzheimer's disease.
Resumen de: WO2025176748A1
The invention provides compounds having the general formula (I) or (II) (I) (II) wherein A, A1, X1, R1, R2, R3, R4, R5, and R6 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
Resumen de: WO2025179044A1
A self-inactivating CRISPR/Cas9 delivery system utilizing a dual vector system may be provided. A first viral vector includes an expression unit for expression of a Cas9 nuclease and a nucleotide sequence encoding an sgRNA targeting a specific genomic locus. The second viral vector includes a nucleotide sequence encoding an sgRNA targeting expression of the Cas9 nuclease by the expression unit. The self-inactivating CRISPR/Cas9 dual vector delivery system can be used for treating a genetic gene-associated disease/disorder and/or a sporadic gene-associated disease/disorder. In embodiments, the disease and/or disorder may be a neurological disease and/or disorder. In embodiments, neurological disease and/or disorder may be Huntington's disease. Methods of treatment, medicaments, and pharmaceutical compositions may be provided.
Resumen de: WO2025175626A1
Provided are a probiotic formulation for preventing or treating Alzheimer's disease and use thereof. The microorganisms in the probiotic formulation consist of Akkermansia muciniphila and Bifidobacterium breve. Akkermansia muciniphila and Bifidobacterium breve can coordinate with each other after being compounded, so as to provide a synergistic effect on alleviating Alzheimer's disease and thereby a new strategy for preventing or treating Alzheimer's disease. Since Akkermania muciniphila and Bifidobacterium breve are both probiotics, a related functional product prepared from Akkermania muciniphila and Bifidobacterium breve may feature good safety and less likelihood of inducing resistance.
Resumen de: US2025270301A1
The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to antibodies, specific for isolated recombinant peptides comprising an epitope from human tau 2N4R and to such antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.
Resumen de: US2025268879A1
The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
Resumen de: US2025268911A1
Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ≤23 and/or a CDR-SOB score of ≥4.5.
Resumen de: US2025268859A1
The invention concerns a compound of formula (I) (I) R1═H, —CH3 or acyl group, preferably R1═—CH3R2═H or halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2═H or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating neurodegenerative diseases when central muscarinic neurotransmission is compromised, wherein said neurodegenerative disease is selected in the group consisting of Alzheimer's Disease (AD), vascular dementia, Dementia with Lewy bodies (DLB), mixed dementia, frontotemporal lobar degeneration (FTLD), and Parkinson's disease (PD).
Resumen de: US2025268822A1
The METHODS, APPARATUSES AND SYSTEMS FOR INSTILLING STEM CELLS AND PHARMACEUTICALS INTO THE HUMAN VENTRICULAR SYSTEM (hereinafter “Ventricular Stem Cell System” or “VSCS”) disclosed herein provide safe and effective techniques for obtaining stem cells and instilling any type of stem cell or pharmaceutical agents into the human ventricular system for treatment of various diseases, including neurodegenerative diseases such as Parkinson's, Alzheimer's, Multiple Sclerosis, and others.
Resumen de: US2025268982A1
Non-aggregating protein analogues of proteins involved in a proteinopathy, for example Alzheimer's disease, are provided. The protein has a beta-sheet aggregation domain, and the non-aggregating protein analogue has a beta-sheet destabilizing modification in the beta-sheet aggregation domain but substantially retains wild type protein function. The beta-sheet destabilizing modification can be a substitution of a naturally occurring amino acid for a non-naturally occurring amino acid. Methods of treating a proteinopathy using the non-aggregating protein analogues and methods of designing a non-aggregating protein analogue are provided.
Resumen de: US2025268981A1
The present disclosure is in the field of diagnostics and therapeutics for Alzheimer's Disease.
Resumen de: US2025268952A1
The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.
Resumen de: US2025268946A1
The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.
Resumen de: US2025270618A1
Provided herein are methods for diagnosing and treating Alzheimer's disease in a subject comprising determining the expression level of three, four or five members of a panel of proteins in a biological sample obtained from the subject.
Resumen de: US2025270565A1
Embodiments of the present disclosure pertain to methods of treating or preventing a neurological disorder in a subject by administering to the subject at least one microRNA (miR-NA), at least one inhibitor of the miRNA, or combinations thereof. Additional embodiments of the present disclosure pertain to compositions that include at least one miRNA of the present disclosure, at least one inhibitor of the miRNAs of the present disclosure, or combinations thereof. In some embodiments, the composition is suitable for use in treating or preventing a neurological disorder in a subject.
Nº publicación: US2025270159A1 28/08/2025
Solicitante:
CHENGDU XINRUI TAIKANG TECH CO LTD [CN]
CHENGDU XINRUI TAIKANG TECHNOLOGY CO., LTD
Resumen de: US2025270159A1
A 1-(cyclobutylidenemethyl)-2,4,5-trimethoxybenzene compound and a preparation method and use thereof are provided, belonging to the field of drug development technology. The prepared 1-(cyclobutylidenemethyl)-2,4,5-trimethoxybenzene compound may be used for the preparation of an antiepileptic drug and drugs for treatment and/or prevention of traumatic craniocerebral injury disorders, ischemic stroke, hemorrhagic stroke, and Parkinson's disease.
BOPI
Sede Electrónica
